@entity11347 is a selective tissue estrogenic activity regulator effective in the management of climacteric symptoms, without stimulating endometrial and breast tissue proliferation. It is a well-tolerated treatment regimen with minor adverse effects. The purpose of the current trial was to investigate the efficacy of @entity11347 administration per os versus per vaginal, concerning the treatment of climacteric symptoms. MATERIAL AND METHOD: A total of 64 post-menopausal healthy @entity1 aged 44-55 years (mean 52,5) were enrolled in the study. The @entity1 were divided into three groups: Group A with 24 @entity1 receiving per os @entity11347 2.5 mg x 1 daily for 6 months, Group B with 21 @entity1 receiving vaginally @entity11347 2.5 mg x 1 for 6 months and Group C--with 19 @entity1 receiving only hygienodietetics advices and psychological support for 6 months. All subjects underwent a physical examination, including a transvaginal ultrasonography for the measurement of endometrial thickness and a mammography for the assessment of breast density. RESULTS: In Group A and B, climacteric symptoms were similarly reduced with non significant differences between groups: 79% (19 @entity1 ) vs 76% (16 @entity1 ) reduction for hot flushes and 83% (20 @entity1 ) vs 76% (16 @entity1 ) for sweating episodes respectively (p > 0.05). Reduction of hot flushes and sweating episodes was observed in only 2 of 19 @entity1 (10.5%) in group C (p < 0.01). Vaginal route had better results on vaginal dryness- @entity546 in group B (in 14 @entity1 taken @entity11347 orally-58% vs 16 @entity1 taken @entity11347 vaginally-76%). No statistically significant difference was found related to urine symptoms between A and B groups. @entity11347 by vaginal route did not cause any severe side effects (apart of a slight discharge) and it was equally (or better) tolerated than oral route. No significant alterations in breast density and BIRADS and no increase in endometrial thickness were observed in all study groups. CONCLUSION: @entity11347 is effective in relieving climacteric symptoms indifferent from applications-modus: orally or vaginally. However, further and larger studies are required to confirm results.

XXXX vaginal versus per os administration in the management of post-menopausal symptoms.

@entity1 :: ('9606', 'Species') :: ['women', 'patients'] @entity546 :: ('MESH:D004414', 'Disease') :: ['dyspareunia'] @entity11347 :: ('MESH:C027385', 'Chemical') :: ['Tibolone', 'tibolone']
@entity11347 :: (MESH:C027385,Chemical) :: ['Tibolone']
